ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for nef y® (epinephrine nasal spray) $15.7 million in revenue, including$12.8 million in neffy U.S. net product revenue in second quarter of 2025 Exhibit 99.1 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) campaign and pediatric co-promote partnership 93% commercial coverage achieved with streamlined prior aut ...